Parallax Volatility Advisers, L.P. Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$233.81 - $287.01 $584,525 - $717,525	2,500 New	2,500 $687,000
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $410,228 - $554,960	2,800 New	2,800 $418,000
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $2.47 Million - $3.21 Million	13,300 New	13,300 $3.16 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $1.82 Million - $2.49 Million	-14,300 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $2.49 Million - $3.26 Million	-15,600 Reduced 52.17%	14,300 $2.43 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $411,616 - $566,048	3,200 Added 11.99%	29,900 $5.07 Million
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $7.71 Million - $9.22 Million	-62,700 Reduced 70.13%	26,700 $3.47 Million
Q3 2020 Nov 13, 2020	BUY	$121.19 - $165.49 $1.98 Million - $2.7 Million	16,300 Added 22.3%	89,400 $13 Million
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $7.02 Million - $10.5 Million	67,400 Added 1182.46%	73,100 $10.8 Million
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $1.47 Million - $2.12 Million	-15,800 Reduced 73.49%	5,700 $623,000
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $1.88 Million - $2.64 Million	21,500 New	21,500 $1.88 Million

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.